AMGN Perlmutter
He takes arrogance to a level that even you might find wearing, Dew! To that extent I have a beef with him.
My point was not that he's necessarily wrong about how practice economics may work to the advantage of d'mab. Not having studied the question and gathered any data, I don't have a pov. My point was that it's for the head of Marketing to make sure this is figured out and to brief the media on it. It's not for the head of R&D, especially not for one whose only pipeline product in 8 or 9 years this is (and it a derivative of a molecule that was already in the pipeline when he showed up to tell everyone how R&D is done). Maybe you need a new Zebra's rule for commercial assessments by R&D chiefs of great white hope drugs.
Best, Corp
Market Data 
Markets 
AI
